These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 26229753)
21. A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus. Tandon T; Dubey AK; Srivastava S; Manocha S; Arora E; Hasan N J Family Med Prim Care; 2019 Mar; 8(3):955-959. PubMed ID: 31041232 [TBL] [Abstract][Full Text] [Related]
22. Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence. Sahay RK; Mittal V; Gopal GR; Kota S; Goyal G; Abhyankar M; Revenkar S Cureus; 2020 Sep; 12(9):e10700. PubMed ID: 33133865 [TBL] [Abstract][Full Text] [Related]
23. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Hassan MH; Abd-Allah GM Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873 [TBL] [Abstract][Full Text] [Related]
24. Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. Kumar S; Pathak AK; Saikia D; Kumar A J Clin Diagn Res; 2015 Dec; 9(12):FC07-10. PubMed ID: 26816909 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Bryson A; Jennings PE; Deak L; Paveliu FS; Lawson M Expert Opin Pharmacother; 2016 Jul; 17(10):1309-16. PubMed ID: 27181910 [TBL] [Abstract][Full Text] [Related]
26. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. McInnes G; Evans M; Del Prato S; Stumvoll M; Schweizer A; Lukashevich V; Shao Q; Kothny W Diabetes Obes Metab; 2015 Nov; 17(11):1085-92. PubMed ID: 26250051 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study. Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178 [TBL] [Abstract][Full Text] [Related]
28. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Deacon CF; Lebovitz HE Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596 [TBL] [Abstract][Full Text] [Related]
29. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes. Hashikata T; Yamaoka-Tojo M; Kakizaki R; Nemoto T; Fujiyoshi K; Namba S; Kitasato L; Hashimoto T; Kameda R; Maekawa E; Shimohama T; Tojo T; Ako J Heart Vessels; 2016 Aug; 31(8):1303-10. PubMed ID: 26266630 [TBL] [Abstract][Full Text] [Related]
30. Metformin and sitAgliptin in patients with impAired glucose tolerance and a recent TIA or minor ischemic Stroke (MAAS): study protocol for a randomized controlled trial. Osei E; Fonville S; Zandbergen AA; Brouwers PJ; Mulder LJ; Lingsma HF; Dippel DW; Koudstaal PJ; den Hertog HM Trials; 2015 Aug; 16():332. PubMed ID: 26242578 [TBL] [Abstract][Full Text] [Related]
31. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296 [TBL] [Abstract][Full Text] [Related]
32. Sulfonylureas and their use in clinical practice. Sola D; Rossi L; Schianca GP; Maffioli P; Bigliocca M; Mella R; Corlianò F; Fra GP; Bartoli E; Derosa G Arch Med Sci; 2015 Aug; 11(4):840-8. PubMed ID: 26322096 [TBL] [Abstract][Full Text] [Related]
33. Results of the Adequacy of glycemiC Control in pAtients with type 2 Diabetes mEllitus treated with Metformin monotherapY at the maximal-tolerated dose (ACCADEMY) study. Giorda CB; Cercone S; Nada E; Endocrine; 2016 Jun; 52(3):507-15. PubMed ID: 26275456 [TBL] [Abstract][Full Text] [Related]
34. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702 [TBL] [Abstract][Full Text] [Related]
35. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T; Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497 [TBL] [Abstract][Full Text] [Related]
36. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. McMurray JJV; Ponikowski P; Bolli GB; Lukashevich V; Kozlovski P; Kothny W; Lewsey JD; Krum H; JACC Heart Fail; 2018 Jan; 6(1):8-17. PubMed ID: 29032139 [TBL] [Abstract][Full Text] [Related]
37. Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Chen K; Kang D; Yu M; Zhang R; Zhang Y; Chen G; Mu Y Diabetes Obes Metab; 2018 Apr; 20(4):1029-1033. PubMed ID: 29095568 [TBL] [Abstract][Full Text] [Related]
38. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Cosenso-Martin LN; Giollo-Júnior LT; Fernandes LAB; Cesarino CB; Nakazone MA; Machado MN; Yugar-Toledo JC; Vilela-Martin JF Acta Diabetol; 2018 Dec; 55(12):1237-1245. PubMed ID: 30094725 [TBL] [Abstract][Full Text] [Related]